1. STING agonists as promising vaccine adjuvants to boost immunogenicity against SARS-related coronavirus derived infection: possible role of autophagy
- Author
-
Aysa Rezabakhsh, M. Reza Sadaie, Alireza Ala, Yousef Roosta, Solomon Habtemariam, Adeleh Sahebnasagh, and Mohammad Rafi Khezri
- Subjects
Autophagy ,COVID-19 ,Immunogenicity ,SARS-CoV-2 ,Stimulator of interferon gene ,Vaccine adjuvant ,Medicine ,Cytology ,QH573-671 - Abstract
Abstract As a major component of innate immunity and a positive regulator of interferons, the Stimulator of interferon gene (STING) has an immunotherapy potential to govern a variety of infectious diseases. Despite the recent advances regarding vaccines against COVID-19, nontoxic novel adjuvants with the potential to enhance vaccine efficacy are urgently desired. In this connection, it has been well-documented that STING agonists are applied to combat COVID-19. This approach is of major significance for boosting immune responses most likely through an autophagy-dependent manner in susceptible individuals against infection induced by severe acute respiratory syndrome Coronavirus (SARS‑CoV‑2). Given that STING agonists exert substantial immunomodulatory impacts under a wide array of pathologic conditions, these agents could be considered novel adjuvants for enhancing immunogenicity against the SARS-related coronavirus. Here, we intend to discuss the recent advances in STING agonists’ recruitment to boost innate immune responses upon vaccination against SARS-related coronavirus infections. In light of the primordial role of autophagy modulation, the potential of being an antiviral vaccine adjuvant was also explored.
- Published
- 2024
- Full Text
- View/download PDF